Revolutionary Implant Developed by Indian Scientist Targets Diabetes Control
A groundbreaking implantable device designed by an Indian researcher in Switzerland offers a new approach to managing diabetes without medication.
The implantable device effectively lowers blood sugar levels in diabetic mice within 90 minutes.
It operates wirelessly and activates automatically when glucose levels exceed a set threshold.
The technology aims to provide a drug-free alternative for diabetes management, addressing limitations of current treatments.
An innovative implantable device has been developed by Indian scientist Debasis Maity and his team at ETH Zurich, Switzerland, aimed at controlling diabetes without the need for insulin or medication. This tiny, wirelessly powered device is designed to remove excess glucose from the bloodstream, demonstrating significant potential for diabetes management. In experiments conducted on diabetic mice, the device successfully improved blood sugar levels within just 90 minutes, while also reducing body weight and triglyceride levels over a six-week period without any adverse effects.
The device is implanted under the skin and is linked to a continuous glucose monitor via a smartphone application. It automatically activates when blood sugar levels surpass a predetermined threshold, allowing for targeted glucose removal. Maity emphasized that while these are proof-of-concept experiments, further refinement and miniaturization of the technology are necessary before human trials can commence.
According to the International Diabetes Federation, nearly 590 million adults globally, including over 90 million in India, are living with diabetes, often alongside obesity. Current treatment methods primarily involve medications that lower glucose levels or body weight, which can lead to side effects and require lifelong adherence. The ETH team, under the guidance of Professor Martin Fussenegger, has created an implant measuring 26mm by 14mm by 5mm, containing an electrocatalyst that adjusts the glucose removal rate based on the body's needs.
The researchers believe this device could serve as a controllable, drug-free therapeutic alternative for diabetes management. They noted that the drug-free mechanism is particularly relevant given the limitations of existing pharmacological therapies, which can be hindered by side effects, cost, and long-term safety concerns. The implant utilizes tiny platinum-coated gold particles embedded in a graphite base to convert glucose into gluconate, which is then excreted by the kidneys.
Looking ahead, Maity's team plans to focus on miniaturizing the implant and integrating it with a wireless charging system and continuous glucose monitoring devices. While experts like Ambrish Mithal from Max Healthcare acknowledge the potential of this technology, they also caution that results observed in lab mice may not directly translate to human efficacy. Nevertheless, Mithal considers this development one of the most innovative approaches to diabetes treatment seen this year.
